144 related articles for article (PubMed ID: 11750032)
21. Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential.
Thompson KH; Liboiron BD; Sun Y; Bellman KD; Setyawati IA; Patrick BO; Karunaratne V; Rawji G; Wheeler J; Sutton K; Bhanot S; Cassidy C; McNeill JH; Yuen VG; Orvig C
J Biol Inorg Chem; 2003 Jan; 8(1-2):66-74. PubMed ID: 12459900
[TBL] [Abstract][Full Text] [Related]
22. Antidiabetic copper(II)-picolinate: impact of the first transition metal in the metallopicolinate complexes.
Yasumatsu N; Yoshikawa Y; Adachi Y; Sakurai H
Bioorg Med Chem; 2007 Jul; 15(14):4917-22. PubMed ID: 17531495
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of insulin signaling pathway in adipocytes by oxovanadium(IV) complexes.
Basuki W; Hiromura M; Adachi Y; Tayama K; Hattori M; Sakurai H
Biochem Biophys Res Commun; 2006 Oct; 349(3):1163-70. PubMed ID: 16970914
[TBL] [Abstract][Full Text] [Related]
24. Morphological analysis of the pancreas and liver in diabetic KK-A(y) mice treated with zinc and oxovanadium complexes.
Moroki T; Yoshikawa Y; Yoshizawa K; Tsubura A; Yasui H
Metallomics; 2014 Sep; 6(9):1632-8. PubMed ID: 24905743
[TBL] [Abstract][Full Text] [Related]
25. The pharmacology of the insulinomimetic effect of zinc complexes.
Sakurai H; Adachi Y
Biometals; 2005 Aug; 18(4):319-23. PubMed ID: 16158223
[TBL] [Abstract][Full Text] [Related]
26. The vanadyl (VO2+) chelate bis(acetylacetonato)oxovanadium(IV) potentiates tyrosine phosphorylation of the insulin receptor.
Ou H; Yan L; Mustafi D; Makinen MW; Brady MJ
J Biol Inorg Chem; 2005 Dec; 10(8):874-86. PubMed ID: 16235045
[TBL] [Abstract][Full Text] [Related]
27. Evidence for the improvement of noninsulin-dependent diabetes mellitus in KKAy mice with daily oral administration of bis(6-methylpicolinato)oxovanadium(IV) complex.
Fujisawa Y; Sakurai H
Chem Pharm Bull (Tokyo); 1999 Nov; 47(11):1668-70. PubMed ID: 10605061
[TBL] [Abstract][Full Text] [Related]
28. The antilipolytic action of bis(alpha-furancarboxylato)oxovanadium(IV) in adipocytes.
Gao L; Niu Y; Liu W; Xie M; Liu X; Chen Z; Li L
Clin Chim Acta; 2008 Feb; 388(1-2):89-94. PubMed ID: 17991430
[TBL] [Abstract][Full Text] [Related]
29. Chemistry and insulin-mimetic properties of bis(acetylacetonate)oxovanadium(IV) and derivatives.
Amin SS; Cryer K; Zhang B; Dutta SK; Eaton SS; Anderson OP; Miller SM; Reul BA; Brichard SM; Crans DC
Inorg Chem; 2000 Feb; 39(3):406-16. PubMed ID: 11229556
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic study on gastrointestinal absorption of insulinomimetic vanadyl complexes in rats by ESR spectroscopy.
Fugono J; Yasui H; Sakurai H
J Pharm Pharmacol; 2001 Sep; 53(9):1247-55. PubMed ID: 11578107
[TBL] [Abstract][Full Text] [Related]
31. Mechanism on insulin-like action of vanadyl sulfate: studies on interaction between rat adipocytes and vanadium compounds.
Nakai M; Watanabe H; Fujiwara C; Kakegawa H; Satoh T; Takada J; Matsushita R; Sakurai H
Biol Pharm Bull; 1995 May; 18(5):719-25. PubMed ID: 7492989
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, characterization and anti-diabetic therapeutic potential of a new benzyl acid-derivatized kojic acid vanadyl complex.
Wei YB; Yang XD
Biometals; 2012 Dec; 25(6):1261-8. PubMed ID: 23015214
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic properties of VO(dmpp)2 as assessed by in vitro and in vivo studies in type 2 diabetic GK rats.
Domingues N; Pelletier J; Ostenson CG; Castro MM
J Inorg Biochem; 2014 Feb; 131():115-22. PubMed ID: 24333827
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
[TBL] [Abstract][Full Text] [Related]
35. Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes.
Kawabe K; Yoshikawa Y; Adachi Y; Sakurai H
Life Sci; 2006 May; 78(24):2860-6. PubMed ID: 16337244
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, spectroscopic, structural and thermal characterizations of vanadyl(IV) adenine complex prospective as antidiabetic drug agent.
El-Megharbel SM; Hamza RZ; Refat MS
Spectrochim Acta A Mol Biomol Spectrosc; 2015 Jan; 135():850-64. PubMed ID: 25150436
[TBL] [Abstract][Full Text] [Related]
37. A new orally active insulin-mimetic vanadyl complex: bis(pyrrolidine-N-carbodithioato)oxovanadium (IV).
Watanabe H; Nakai M; Komazawa K; Sakurai H
J Med Chem; 1994 Apr; 37(7):876-7. PubMed ID: 8151615
[No Abstract] [Full Text] [Related]
38. Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV).
Willsky GR; Goldfine AB; Kostyniak PJ; McNeill JH; Yang LQ; Khan HR; Crans DC
J Inorg Biochem; 2001 May; 85(1):33-42. PubMed ID: 11377693
[TBL] [Abstract][Full Text] [Related]
39. Insulin-enhancing activity of a dinuclear vanadium complex: 5-chloro-salicylaldhyde ethylenediamine oxovanadium(V) and its permeability and cytotoxicity.
Xie MJ; Yang XD; Liu WP; Yan SP; Meng ZH
J Inorg Biochem; 2010 Aug; 104(8):851-7. PubMed ID: 20434776
[TBL] [Abstract][Full Text] [Related]
40. [Insulino-mimetic effects of bis (alpha-furancarboxylato) oxovanadium (IV) in vitro].
Li YR; Gao LH; Ma YL; Niu YF; Liu WP; Li L
Yao Xue Xue Bao; 2008 Mar; 43(3):318-22. PubMed ID: 18630272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
